Jupiter Topco LLC Acquires Shares of 98,261 ADMA Biologics Inc $ADMA

Jupiter Topco LLC bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 98,261 shares of the biotechnology company’s stock, valued at approximately $822,000.

A number of other institutional investors have also modified their holdings of ADMA. BlackRock Inc. purchased a new stake in ADMA Biologics in the 2nd quarter valued at $321,037,000. State Street Corp increased its stake in ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after purchasing an additional 35,614 shares during the period. Sachem Head Capital Management LP increased its stake in ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after buying an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors raised its holdings in shares of ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ADMA. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Mizuho reduced their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Raymond James Financial began coverage on ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.67.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $9.62 on Monday. ADMA Biologics Inc has a one year low of $7.21 and a one year high of $20.46. The company has a market cap of $2.15 billion, a P/E ratio of 13.74 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The firm has a fifty day moving average of $9.15 and a two-hundred day moving average of $10.27.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. The business’s quarterly revenue was up 2.0% compared to the same quarter last year. On average, analysts forecast that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.